Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + sintilimab + chemotherapy in advanced pancreatic cancer
ChiCTR2300076306Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and sintilimab in pancreatic cancer (PC), sponsored by Union Hospital. Primary endpoint: Objective response rate. Started Oct 2023; status: recruiting.
02
Drugs
fruquintinibsintilimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300076306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076306.